Aptevo Therapeutics Inc. 8-K

What Happened

• On May 25, 2026 Aptevo Research and Development LLC (a subsidiary of Aptevo Therapeutics) entered a Collaboration Agreement and a related Supply Agreement with Niowave, Inc. to develop a potential human therapeutic combining Aptevo’s proprietary molecules (including APVO455) with Niowave’s radioisotopes (including Actinium‑225).
• Concurrently, Aptevo executed a Stock Purchase Agreement under which it sold 98,522 shares of common stock and accompanying warrants to purchase 53,201 shares to Niowave in a private placement for approximately $500,000 (combined price $5.075 per share). The Initial Niowave Private Placement closed on May 26, 2026. A press release about the transactions was issued May 27, 2026.

Key Details

• Transaction date: Collaboration, supply and stock purchase agreements executed May 25, 2026; private placement closed May 26, 2026; press release May 27, 2026.
• Financing: 98,522 shares sold plus warrants to buy 53,201 shares at $8.00 per share; total proceeds ≈ $500,000; warrants expire May 25, 2031 and may be exercised for cash or on a cashless basis.
• Additional investment option: Niowave may purchase up to ~97,373 additional shares before the earlier of (i) the third anniversary of the Collaboration Agreement or (ii) approval of an IND for a Combination Product, subject to ownership caps.
• Ownership limits & exercise caps: Warrant exercise limited so Niowave (with affiliates) won’t exceed 4.99% ownership by default (can elect up to 9.99% with notice); Additional placements capped so Niowave won’t be deemed beneficial owner of >19.99% upon closing.

Why It Matters

• The collaboration pairs Aptevo’s therapeutic molecules (e.g., APVO455) with Niowave’s radioisotopes (Actinium‑225), which could advance development of targeted radiotherapeutics — a strategic R&D partnership rather than an acquisition.
• The private placement provides immediate non-dilutive (limited) capital of roughly $500K and further aligns Niowave as a partner with both development and potential future investment rights.
• Investors should note potential dilution from warrants and additional share placements (subject to percentage caps), the supply agreement that can ensure access to key isotopes if Niowave opts out at certain points, and that full agreement texts will be filed as exhibits in Aptevo’s upcoming 10‑Q.